Viking Therapeutics (VKTX) Net Cash Flow (2014 - 2026)

Viking Therapeutics (VKTX) has 13 years of Net Cash Flow data on file, last reported at -$47.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 523.6% year-over-year to -$47.7 million; the trailing twelve-month figure through Mar 2026 stood at $80.2 million (up 150.89% YoY), and the FY2025 full-year result was $139.1 million, up 584.95% from the prior year.
• Net Cash Flow declined to -$47.7 million in Q1 2026, from $65.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $140.1 million in Q1 2024 to a low of -$151.7 million in Q2 2024.
• A 5-year average of $5.4 million and a median of $6.5 million in 2024 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow surged 1195.85% in 2023 and plunged 523.6% in 2026, its largest moves.
• Tracing VKTX's Net Cash Flow over 5 years: stood at $7.1 million in 2022, then surged by 158.1% to $18.3 million in 2023, then tumbled by 229.08% to -$23.6 million in 2024, then soared by 377.26% to $65.4 million in 2025, then plunged by 172.92% to -$47.7 million in 2026.
• Business Quant data shows VKTX's Net Cash Flow at -$47.7 million in Q1 2026, $65.4 million in Q4 2025, and $66.5 million in Q3 2025.